Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (OTCQX: VXRT) is a clinical-stage biotechnology company developing oral recombinant vaccines delivered as pills, and its news flow reflects progress across multiple vaccine programs and corporate developments. The company regularly issues updates on its clinical trials for oral pill vaccine candidates targeting coronavirus, norovirus and influenza, as well as a therapeutic HPV vaccine candidate that it identifies as its first immune-oncology program.
Readers following Vaxart news can expect detailed reports on clinical data from its oral vaccine platform. For example, the company has announced Phase 1 results for a bivalent norovirus pill vaccine in lactating women, describing safety, tolerability and increases in norovirus-specific IgA in serum and breast milk, along with evidence of norovirus-specific IgA in infant stool. Vaxart has also highlighted data from second-generation norovirus constructs showing stronger blocking antibody responses and robust fecal IgA increases, and has presented these findings at scientific conferences such as the International Calicivirus Conference, World Vaccine Congress and IDWeek.
Vaxart’s news also covers its COVID-19 oral pill vaccine program, including enrollment and follow-up in a large Phase 2b trial funded under a Project NextGen/BARDA contract, and regulatory and funding updates such as a stop work order that delimited certain activities while maintaining support for follow-up of enrolled participants. In addition, the company has reported on an exclusive, worldwide license and collaboration agreement with Dynavax Technologies Corporation for its oral COVID-19 vaccine candidate, outlining the structure of upfront payments, an equity investment, and potential milestones and royalties.
Beyond clinical and partnership news, Vaxart issues releases on corporate actions, including stock listing changes, governance matters and capital markets events such as conference presentations and investor calls. Investors and observers can use this news feed to track the evolution of Vaxart’s oral vaccine platform, key trial readouts, collaboration milestones and changes in its trading venue and cost management initiatives.
Vaxart, Inc. (Nasdaq: VXRT) has initiated a Phase 1b trial assessing its oral norovirus vaccine in elderly participants aged 55 to 80. This first subject enrollment marks a significant step in addressing the lack of approved vaccines for norovirus, which causes considerable illness and deaths annually among older adults. The study aims to evaluate safety and immunogenicity, with results expected to inform future COVID-19 vaccine development. Norovirus is responsible for 56,000 to 71,000 hospitalizations and 570 to 800 deaths each year in the U.S., with a substantial economic burden of $10.5 billion.
Vaxart (Nasdaq: VXRT) has initiated a Phase 1b trial for its norovirus oral vaccine candidate, enrolling the first subject. This study aims to assess various dosing regimens' safety and immunogenicity. Norovirus causes approximately 15% of U.S. children under five to fall ill annually, resulting in a $10.5 billion economic burden. The trial design includes 30 subjects aged 18-55, divided into three cohorts, focusing on optimal booster timing. Results may also influence Vaxart's COVID-19 oral vaccine program, entering Phase 2 trials mid-year.
Vaxart (Nasdaq: VXRT) announced positive results from its Phase I COVID-19 vaccine trial, highlighting that its oral vaccine candidate, VXA-CoV2-1, induces higher CD8+ T-cell responses compared to the Moderna and Pfizer vaccines. The vaccine induces mucosal immunity and shows cross-reactivity against various coronaviruses.
CEO Andrei Floroiu emphasized the potential benefits of these immune responses, while Chief Scientific Officer Dr. Sean Tucker noted their importance in fighting severe infections. The study's comparative data suggests Vaxart's vaccine may offer unique advantages against evolving variants.
Vaxart, Inc. (Nasdaq: VXRT) announced its progress on three oral tablet COVID-19 vaccine candidates, advancing VXA-CoV2-1 to Phase II and two S-only constructs to Phase I/II. The company aims to start four clinical trials for its oral norovirus vaccine in 2021. As of March 31, 2021, Vaxart reported cash equivalents of $177.3 million, a rise from $126.9 million at the end of 2020. However, the company faced a net loss of $16.0 million in Q1 2021, with revenue dropping to $506,000, primarily due to reduced royalty revenue.
Vaxart (Nasdaq: VXRT) announced that its founder and chief scientific officer, Sean Tucker, Ph.D., will present at the virtual World Vaccine Congress from May 4-6, 2021. The presentation, titled Vaxart oral COVID-19 vaccine; hold the ice and the needles, focuses on the company’s innovative oral tablet vaccine designed to combat COVID-19 without refrigeration. This congress is a premier event covering the entire vaccine value chain, highlighting scientific advancements and collaborations.
Vaxart, a clinical-stage biotechnology company, announced a webinar on May 3, 2021, discussing T-cell responses in COVID-19 vaccines, featuring Dr. Mark Davis from Stanford University. This event comes amid concerns over new COVID-19 variants and aims to highlight the potential of T-cell engagement alongside antibody production.
Vaxart will present new data from its Phase I trial for its VXA-CoV2-1 vaccine, which suggests it may offer protection against emerging strains. This data could play a significant role in vaccine efficacy against variants.
Vaxart, Inc. (Nasdaq: VXRT) announced the appointment of Dr. David Wheadon to its Board of Directors, leveraging his extensive experience in global health policy and regulatory affairs. Dr. Wheadon, previously at AstraZeneca, aims to guide Vaxart as it advances its oral vaccine portfolio, including a COVID-19 candidate set for Phase 2 trials. Vaxart’s innovative tablet vaccines promise to simplify vaccination logistics, reducing the need for refrigeration and needle use. This strategic addition to the board is expected to enhance Vaxart's leadership and development capabilities.
Nearly 19 million Americans who currently refuse vaccines would consider vaccination if offered a pill option, according to a Vaxart commissioned poll. Conducted by Quadrant Strategies, the survey indicates that 70% of respondents prefer a pill over injection. The potential impact includes improving vaccination rates among underrepresented minority groups. Vaxart has completed Phase 1 of its oral COVID-19 vaccine, achieving necessary safety and immunogenicity endpoints. The findings emphasize the need for alternatives to needle injections to enhance public health efforts.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 – Vaxart, a clinical-stage biotechnology company focused on oral recombinant vaccines, announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The presentation will be available on-demand starting at 7 a.m. ET on March 9 through the conference portal and on Vaxart’s website afterward. Vaxart is developing several oral vaccines targeting coronavirus, Norovirus, seasonal influenza, respiratory syncytial virus (RSV), and human papillomavirus (HPV), aiming to revolutionize vaccine delivery and storage.
Vaxart, Inc. plans to advance its oral COVID-19 vaccine candidate, VXA-CoV2-1, to Phase 2 testing in Q2 2021. The company reported a cash balance of $126.9 million as of December 31, 2020, reflecting significant capital influx from various funding sources. The fourth-quarter revenue was $356,000, down from $3.9 million in 2019, primarily due to a drop in royalty revenue. The net loss for Q4 2020 was $13.9 million, with R&D expenses increasing to $8.6 million driven by COVID-19 vaccine developments. A strategic conference call is scheduled for March 2, 2021.